Ahn Sung-Ho, Lee Ji-Sung, Kim Young-Hak, Kim Bum Joon, Kim Yeon-Jung, Kang Dong-Wha, Kim Jong S, Kwon Sun U
Department of Neurology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.
Department of Neurology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Korea.
J Stroke. 2017 Sep;19(3):312-322. doi: 10.5853/jos.2016.01942. Epub 2017 Sep 6.
Troponin, a marker of myocardial injury, frequently increases and is related with poor outcome in ischemic stroke patients. However, the long-term outcome of this elevation remains uncertain. We, therefore, investigated the prognostic significance of troponin elevation for long-term mortality, and explored factors affecting troponin elevation after ischemic stroke.
We retrospectively analyzed the medical data of stroke patients who were admitted within 24 hours of symptom onset and underwent a serum cardiac troponin I test at admission during a five-year period. Information on mortality as the outcome was obtained from the National Death Certificate system.
A total of 1,692 patients were eligible for inclusion with 33 months of median follow-up. Troponin elevation that exceeded the 99th percentile (>0.04 ng/mL) of values was detected in 166 patients (9.8%). After adjusting for baseline characteristics, troponin elevation was associated with previous ischemic heart disease and congestive heart failure, comorbid atrial fibrillation and active cancer, and increased National Institutes of Health Stroke Scale score. Patients with troponin elevation had a high risk of overall death (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.40-2.40), including stroke-related (HR 1.71, 95% CI 1.14-2.55), cardiac-related (HR 3.17, 95% CI 1.49-6.74), and cancer-related (HR 1.98, 95% CI 1.14-3.45) death than those without troponin elevation.
Troponin elevation in the acute stage of ischemic stroke was associated with long-term mortality, mainly due to increased stroke- and cancer-related death in the first year and cardiacrelated death in the later period.
肌钙蛋白作为心肌损伤的标志物,在缺血性脑卒中患者中常升高且与不良预后相关。然而,这种升高的长期预后仍不确定。因此,我们研究了肌钙蛋白升高对长期死亡率的预后意义,并探讨了缺血性脑卒中后影响肌钙蛋白升高的因素。
我们回顾性分析了症状发作24小时内入院且在五年期间入院时接受血清心肌肌钙蛋白I检测的脑卒中患者的医疗数据。作为结局的死亡率信息来自国家死亡证明系统。
共有1692例患者符合纳入标准,中位随访时间为33个月。166例患者(9.8%)检测到肌钙蛋白升高超过第99百分位数(>0.04 ng/mL)。在调整基线特征后,肌钙蛋白升高与既往缺血性心脏病、充血性心力衰竭、合并心房颤动和活动性癌症以及美国国立卫生研究院卒中量表评分增加相关。与肌钙蛋白未升高的患者相比,肌钙蛋白升高的患者总体死亡风险较高(风险比[HR] 1.83,95%置信区间[CI] 1.40 - 2.40),包括与卒中相关的死亡(HR 1.71,95% CI 1.14 - 2.55)、与心脏相关的死亡(HR 3.17,95% CI 1.49 - 6.74)和与癌症相关的死亡(HR 1.98,95% CI 1.14 - 3.45)。
缺血性脑卒中急性期肌钙蛋白升高与长期死亡率相关,主要是由于第一年卒中及癌症相关死亡增加以及后期心脏相关死亡增加。